NO20082167L - Anti-Myostatin-antistoffer - Google Patents

Anti-Myostatin-antistoffer

Info

Publication number
NO20082167L
NO20082167L NO20082167A NO20082167A NO20082167L NO 20082167 L NO20082167 L NO 20082167L NO 20082167 A NO20082167 A NO 20082167A NO 20082167 A NO20082167 A NO 20082167A NO 20082167 L NO20082167 L NO 20082167L
Authority
NO
Norway
Prior art keywords
antibodies
myostatin antibodies
myostatin
increasing
immunoconjugates
Prior art date
Application number
NO20082167A
Other languages
English (en)
Inventor
Rosamund Carol Smith
Julian Davies
Bryan Edward Jones
Pamela Jean Mitchell
Rong Wang
Andrew Ihor Korytko
Linda O O'bryan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20082167L publication Critical patent/NO20082167L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

Sammendrag Anti-myostatin antistoffer er identifisert som er karakterisert til å ha høy affinitet og kan være kimære, humaniserte eller fullstendig humane antistoffer, immunkonjugater av antistoffene eller antigen-bindende-fragmenter derav. Antistoffene av oppfinnelsen er nyttige for å øke muskelmasse, øke beintetthet, eller for behandlingen av ulike lidelser i pattedyr og fuglearter.
NO20082167A 2005-10-12 2008-05-09 Anti-Myostatin-antistoffer NO20082167L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72573805P 2005-10-12 2005-10-12
PCT/US2006/038817 WO2007047112A2 (en) 2005-10-12 2006-10-05 Anti-myostatin antibodies

Publications (1)

Publication Number Publication Date
NO20082167L true NO20082167L (no) 2008-07-10

Family

ID=37681692

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082167A NO20082167L (no) 2005-10-12 2008-05-09 Anti-Myostatin-antistoffer

Country Status (23)

Country Link
US (2) US7632499B2 (no)
EP (2) EP2816058B1 (no)
JP (1) JP5031756B2 (no)
KR (1) KR101128548B1 (no)
CN (1) CN101282992B (no)
AU (1) AU2006303921B2 (no)
BR (1) BRPI0617345A2 (no)
CA (1) CA2624935C (no)
DK (2) DK1951755T3 (no)
EA (1) EA015903B1 (no)
ES (2) ES2657292T3 (no)
HK (1) HK1118564A1 (no)
HR (1) HRP20150176T1 (no)
HU (1) HUE036566T2 (no)
IL (1) IL189580A (no)
LT (1) LT2816058T (no)
NO (1) NO20082167L (no)
PL (2) PL2816058T3 (no)
PT (2) PT1951755E (no)
RS (2) RS56755B1 (no)
SI (2) SI1951755T1 (no)
UA (1) UA92504C2 (no)
WO (1) WO2007047112A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1581649T1 (sl) 2002-12-20 2011-09-30 Amgen Inc Vezna sredstva, ki zavirajo miostatin
US7635760B2 (en) * 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
KR101123531B1 (ko) * 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
PL2307457T5 (pl) 2008-06-25 2022-12-27 Novartis Ag Stabilne i rozpuszczalne przeciwciała hamujące tnf
SI2307458T1 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
UY32341A (es) * 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
WO2012024242A1 (en) * 2010-08-16 2012-02-23 Amgen Inc. Antibodies that bind myostatin, compositions and methods
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
EP2554353B1 (de) 2011-08-05 2017-06-07 Trisa Holding AG Verfahren zur Herstellung einer Zahnbürste und Zahnbürste
EP2780368B1 (en) 2011-11-14 2018-01-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
DK3835310T3 (da) 2012-09-13 2024-06-03 Bristol Myers Squibb Co Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
CN112933223A (zh) 2012-10-24 2021-06-11 细胞基因公司 用于治疗贫血的方法
WO2014119634A1 (ja) * 2013-01-30 2014-08-07 独立行政法人国立精神・神経医療研究センター 筋増加剤及びそれを含む医薬組成物
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
PT2981822T (pt) 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
JP2017510622A (ja) 2014-01-27 2017-04-13 ノバルティス アーゲー 筋萎縮を予測するバイオマーカー、方法および使用
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
US10307480B2 (en) * 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
CA2982810A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EP3350220B1 (en) 2015-09-15 2021-05-19 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
KR20210082548A (ko) 2016-06-13 2021-07-05 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
MY193497A (en) 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
SI3565592T1 (sl) 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
EP3758800A1 (en) 2018-03-01 2021-01-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
CN113195532A (zh) 2018-12-18 2021-07-30 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
DE69432815T2 (de) 1993-03-19 2003-12-11 The Johns Hopkins University School Of Medicine, Baltimore Wachstumsfaktor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
KR100227406B1 (ko) * 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
DE69636868T2 (de) 1995-08-29 2007-10-25 Kirin Beer Kabushiki Kaisha Chimäres tier und methode zu dessen herstellung
US20020165350A1 (en) 1996-11-13 2002-11-07 Tasuku Honjo Novel polypeptide, a method of producing it, and utility of the polypeptide
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
WO1999024057A2 (en) 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
DE69941116D1 (de) 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
BR0008188A (pt) * 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US20040138118A1 (en) 2002-09-16 2004-07-15 Neil Wolfman Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
SI1581649T1 (sl) * 2002-12-20 2011-09-30 Amgen Inc Vezna sredstva, ki zavirajo miostatin
CN1829532A (zh) 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
NZ529860A (en) * 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
RU2422460C2 (ru) * 2003-12-31 2011-06-27 Шеринг-Плоу Лтд. Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного
WO2005094446A2 (en) 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
MX2007011400A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
AU2006239860B2 (en) * 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
US20090215671A1 (en) * 2005-05-27 2009-08-27 The Regents Of The University Of California Compositions And Methods For Treatment of Neural Disorders Using Transforming Growth Factor-Beta Superfamily Proteins And Their Antagonists
ES2659114T3 (es) * 2005-08-19 2018-03-13 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途

Also Published As

Publication number Publication date
AU2006303921A1 (en) 2007-04-26
SI2816058T1 (en) 2018-02-28
HUE036566T2 (hu) 2018-07-30
RS54046B1 (en) 2015-10-30
ES2533462T3 (es) 2015-04-10
IL189580A (en) 2012-07-31
EP2816058B1 (en) 2017-12-13
PT2816058T (pt) 2018-02-27
JP2009511579A (ja) 2009-03-19
EA200801065A1 (ru) 2008-08-29
US20090131638A1 (en) 2009-05-21
SI1951755T1 (sl) 2015-02-27
RS56755B1 (sr) 2018-04-30
CN101282992A (zh) 2008-10-08
KR101128548B1 (ko) 2012-03-23
KR20080049104A (ko) 2008-06-03
CA2624935C (en) 2011-11-29
HRP20150176T1 (en) 2015-03-27
US8066995B2 (en) 2011-11-29
IL189580A0 (en) 2008-08-07
AU2006303921B2 (en) 2011-05-12
HK1118564A1 (en) 2009-02-13
US7632499B2 (en) 2009-12-15
EP2816058A1 (en) 2014-12-24
UA92504C2 (en) 2010-11-10
US20100080811A1 (en) 2010-04-01
PL1951755T3 (pl) 2015-05-29
LT2816058T (lt) 2018-03-12
DK1951755T3 (en) 2015-01-19
EA015903B1 (ru) 2011-12-30
WO2007047112A2 (en) 2007-04-26
PT1951755E (pt) 2015-03-16
PL2816058T3 (pl) 2018-05-30
EP1951755A2 (en) 2008-08-06
ES2657292T3 (es) 2018-03-02
CN101282992B (zh) 2013-02-13
EP1951755B1 (en) 2015-01-07
JP5031756B2 (ja) 2012-09-26
WO2007047112A3 (en) 2007-08-16
CA2624935A1 (en) 2007-04-26
BRPI0617345A2 (pt) 2011-07-26
DK2816058T3 (en) 2018-01-22

Similar Documents

Publication Publication Date Title
NO20082167L (no) Anti-Myostatin-antistoffer
CY1120365T1 (el) Αντισωματα εναντι της il-17
NO20082073L (no) Anti-myostatin-antistoffer
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
NO20064788L (no) Anti-myostatin-anistoffer
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
NO20074563L (no) Novel anti-plgf antibody
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MY149129A (en) Anti-sclerostin antibodies
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2008030706A3 (en) Anti-myostatin antibodies
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2022004712A (es) Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης
EA202092121A1 (ru) Антитела против cd73 и их применения
EA202091631A1 (ru) Антитела к тканевому фактору, конъюгаты антитело-лекарственное средство и связанные способы

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application